Octave Presents New Data at CMSC Annual Meeting 2023, Adding to Growing Evidence Supporting All Dimensions of its Comprehensive Precision Care Solution for Multiple Sclerosis
Retrieved on:
Friday, June 2, 2023
Biotechnology, Health, Neurology, Biometrics, Other Health, Radiology, Pharmaceutical, Research, Managed Care, Infectious Diseases, General Health, Genetics, Health Technology, Science, Single, DMT, Silent, MSN, Hospital, UTI, Urinary tract infection, University of Michigan Institute for Social Research, Medicine, Robustness, Emergent, Multiple sclerosis, BSN, CMSC, MS, Nursing, DMTS, DSM-IV codes, MRI, DO, PHN, Acquisition, MD, Patient, Physician, Neuroradiology, Center of excellence, Annual general meeting, Biology, RN, Poster, Hanusch, Medical imaging, Pharmaceutical industry, Octave
The data adds to the growing evidence supporting all dimensions of the company’s comprehensive Precision Care Solution for MS.
Key Points:
- The data adds to the growing evidence supporting all dimensions of the company’s comprehensive Precision Care Solution for MS.
- “The robustness of learned protein signatures across datasets is reassuring evidence for the clinical utility of this methodology,” Dr. Foley said.
- Discrepancies in clinical impressions, treatment recommendations, and follow-up orders may significantly impact patient outcomes and cost of care.
- The posters and oral presentation presented by Octave at this year’s CMSC Annual Meeting showcase the growing breadth of data supporting its Precision Care Solution.